Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

N. M. Tannir*, L. Albigès, D. F. McDermott, M. Burotto, T. K. Choueiri, H. J. Hammers, P. Barthélémy, E. R. Plimack, C. Porta, S. George, F. Donskov, M. B. Atkins, H. Gurney, C. K. Kollmannsberger, M. O. Grimm, C. Barrios, Y. Tomita, D. Castellano, V. Grünwald, B. I. RiniR. Jiang, H. Desilva, V. Fedorov, C. W. Lee, R. J. Motzer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science